Therma Bright Secures Purchase Order For 1,750 Venowave W5 Units From National Distributor - DME Authority of Nashville, TN
Therma Bright (TBRIF) has secured a significant purchase order for 1,750 Venowave VW5 units from DME Authority, a national distributor based in Nashville, Tennessee. The order follows successful pilot trials and a previously signed Letter of Intent (LOI) positioning DME as a 'Premier Distributor Partner'. The purchase order represents potential HCPCS code reimbursements totaling $1,434,212 USD (approximately $2,051,602 CAD).
The company has initiated production with a new manufacturing partner to meet growing demand from their national distribution network. This development comes amid a promising market outlook, with the global compression therapy market valued at $4.18 billion in 2024 and projected to reach $6.72 billion by 2033, representing a CAGR of 7.30%.
Therma Bright (TBRIF) ha ottenuto un'importante ordinazione per 1.750 unità di Venowave VW5 da DME Authority, un distributore nazionale con sede a Nashville, Tennessee. L'ordine segue prove pilota di successo e una Lettera di Intenti (LOI) firmata in precedenza che posiziona DME come 'Partner Distributore Premiere'. L'ordinazione rappresenta potenziali rimborsi del codice HCPCS per un totale di 1.434.212 USD (circa 2.051.602 CAD).
L'azienda ha avviato la produzione con un nuovo partner produttivo per soddisfare la crescente domanda della loro rete di distribuzione nazionale. Questo sviluppo arriva in un contesto di mercato promettente, con il mercato globale della terapia compressiva valutato a 4,18 miliardi di dollari nel 2024 e previsto per raggiungere 6,72 miliardi di dollari entro il 2033, rappresentando un CAGR del 7,30%.
Therma Bright (TBRIF) ha asegurado un pedido importante de 1,750 unidades de Venowave VW5 de DME Authority, un distribuidor nacional con sede en Nashville, Tennessee. El pedido sigue a pruebas piloto exitosas y una Carta de Intención (LOI) firmada anteriormente que posiciona a DME como 'Socio Distribuidor Premier'. El pedido representa reembolsos potenciales del código HCPCS por un total de $1,434,212 USD (aproximadamente $2,051,602 CAD).
La empresa ha iniciado la producción con un nuevo socio de fabricación para satisfacer la creciente demanda de su red de distribución nacional. Este desarrollo se produce en un contexto de mercado prometedor, con el mercado global de terapia de compresión valorado en $4.18 mil millones en 2024 y proyectado para alcanzar $6.72 mil millones para 2033, lo que representa un CAGR del 7.30%.
Therma Bright (TBRIF)는 테네시주 내슈빌에 본사를 둔 국가 유통업체인 DME Authority로부터 1,750개의 Venowave VW5 유닛에 대한 중요한 구매 주문을 확보했습니다. 이 주문은 성공적인 파일럿 시험과 DME를 '프리미어 배급 파트너'로 위치시키는 이전에 서명된 의향서(LOI)에 따른 것입니다. 이 구매 주문은 총 $1,434,212 USD (약 2,051,602 CAD)의 HCPCS 코드 환급 가능성을 나타냅니다.
회사는 국가 유통망의 증가하는 수요를 충족하기 위해 새로운 제조 파트너와 함께 생산을 시작했습니다. 이 개발은 2024년 전 세계 압축 요법 시장이 41.8억 달러로 평가되고 2033년까지 67.2억 달러에 이를 것으로 예상되는 유망한 시장 전망 속에서 이루어졌으며, 연평균 성장률(CAGR)은 7.30%에 달합니다.
Therma Bright (TBRIF) a obtenu une commande importante de 1 750 unités de Venowave VW5 de DME Authority, un distributeur national basé à Nashville, Tennessee. Cette commande fait suite à des essais pilotes réussis et à une Lettre d'Intention (LOI) signée précédemment, positionnant DME en tant que 'Partenaire Distributeur Premier'. La commande représente des remboursements potentiels du code HCPCS totalisant 1 434 212 USD (environ 2 051 602 CAD).
L'entreprise a lancé la production avec un nouveau partenaire de fabrication pour répondre à la demande croissante de son réseau de distribution national. Ce développement survient dans un contexte de marché prometteur, le marché mondial de la thérapie de compression étant évalué à 4,18 milliards de dollars en 2024 et projetté d'atteindre 6,72 milliards de dollars d'ici 2033, représentant un TCAC de 7,30%.
Therma Bright (TBRIF) hat einen bedeutenden Kaufauftrag über 1.750 Venowave VW5-Einheiten von DME Authority, einem nationalen Distributor mit Sitz in Nashville, Tennessee, gesichert. Der Auftrag folgt auf erfolgreiche Pilotversuche und einen zuvor unterzeichneten Letter of Intent (LOI), der DME als 'Premier Distributor Partner' positioniert. Der Kaufauftrag repräsentiert potenzielle HCPCS-Code-Erstattungen in Höhe von 1.434.212 USD (etwa 2.051.602 CAD).
Das Unternehmen hat mit einem neuen Fertigungspartner die Produktion aufgenommen, um die wachsende Nachfrage aus seinem nationalen Vertriebsnetz zu decken. Diese Entwicklung erfolgt vor dem Hintergrund eines vielversprechenden Marktumfelds, wobei der globale Markt für Kompressionstherapie im Jahr 2024 auf 4,18 Milliarden USD geschätzt wird und bis 2033 auf 6,72 Milliarden USD anwachsen soll, was einem CAGR von 7,30% entspricht.
- Secured purchase order for 1,750 Venowave VW5 units worth $1.43M USD
- Established partnership with national distributor DME Authority
- New manufacturing partnership initiated to meet growing demand
- Operating in a growing market with 7.30% CAGR projection through 2033
- None.
National Distributor Eager To Begin Sales & Marketing Of Vascular Compression Therapy Solutions
Toronto, Ontario--(Newsfile Corp. - January 21, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that it has secured a purchase order for 1,750 Venowave VW5 from national distribution partner DME Authority of Nashville, Tennessee. DME, along with their partner network, was just one of the Company's national distributors who have experienced successful pilot trials.
Last month, distribution partner DME Authority signed a Letter of Intent (LOI) for distributing the Venowave VW5 to its U.S. distribution network. This purchase order brings both companies one step closer to the outlined LOI that positions DME as a 'Premier Distributor Partner' for Therma Bright. This initial purchase order for 1750 Venowave VW5 units offers HCPCS code reimbursements that total
"It is very exciting to see our distribution program with DME come to fruition," shared Rob Fia, CEO of Therma Bright. "Our current inventory is seeing great traction, so we've begun the process with our new manufacturing partner to begin production on new inventory, which we anticipate will arrive to meet the demand of our growing national distribution network. As always, we will keep the market updated on our progress with sales and manufacturing."
The global compression therapy market was valued at
About Venowave VW5
The Venowave VW5 is a compact, battery-operated peristaltic pump designed to diminish post-op pain & swelling and enhance blood circulation while harnessing the multitude of advantages that come with increased venous blood flow by
About DME Authority, LLC
DME Authority partners with a select network of top-tier medical distributors and healthcare providers to deliver outcome-driven solutions that set new standards for patient care. By aligning with forward-thinking organizations, we bring innovative sales and distribution strategies to life, backed by comprehensive billing expertise and strategic funding programs. Our unique approach ensures our partners achieve unmatched success while transforming healthcare delivery across the U.S. Visit: www.dmeauthority.com
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237912
FAQ
What is the value of Therma Bright's (TBRIF) recent Venowave VW5 purchase order?
How many Venowave VW5 units did DME Authority order from Therma Bright (TBRIF)?
What is the projected growth of the compression therapy market by 2033?
Who is Therma Bright's (TBRIF) new distribution partner for Venowave VW5?
